Journal article
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial
Abstract
AIMS: The OASIS-6 trial demonstrated the benefit of fondaparinux in patients with ST-segment elevation myocardial infarction (STEMI) not undergoing primary percutaneous coronary intervention. Elderly compared to younger patients are at higher risk of bleeding and could have a different balance of benefits and risks when treated with antithrombotic therapy.
METHODS AND RESULTS: We explored the efficacy and safety of fondaparinux compared to …
Authors
van Rees Vellinga TE; Peters RJG; Yusuf S; Afzal R; Chrolavicius S; O'Donnell M; Mehta SR; Pluta W; Sacha J; Eikelboom JW
Journal
American Heart Journal, Vol. 160, No. 6, pp. 1049–1055
Publisher
Elsevier
Publication Date
12 2010
DOI
10.1016/j.ahj.2010.08.038
ISSN
0002-8703